Background -Interstitial lung diseases are characterised by the recruitment of mononuclear cells to disease sites where maturation occurs and activation products, including lysozyme (LZM), are released. Analysis of in vitro cell culture supernatants for activation products masks the functional heterogeneity of cell populations. It is therefore necessary to examine the secretion of activation products by single cells to assess whether the activation ofnewly recruited mononuclear phagocytes at the sites of disease in the lung is uniform and controlled by the local microenvironment. Methods -The reverse haemolytic plaque assay was used to evaluate, at a single cell level, the ability ofbronchoalveolar lavage (BAL) fluid from seven patients with sarcoidosis to activate Ficoll-Hypaque-separated peripheral blood mononuclear cells by comparison with BAL fluid from six normal volunteers and nine patients with systemic sclerosis. Monolayers of peripheral blood mononuclear cells and sheep red blood cells were cultured either alone or in the presence of 20% (vlv) (Thorax 1994;49:1146-1151 Sarcoidosis is characterised by the accumulation at disease sites ofmononuclear cells resulting in the formation of epithelioid cell granulomas."2 Circulating monocytes which are attracted to disease sites are subjected to the influence of local proinflammatory signals resulting in phenotypic and functional changes as they undergo maturation and activation.3 One of the activation products of stimulated mononuclear phagocytes is lysozyme (LZM),4 and measurements of LZM concentration have been used as an index of active disease.56 The primary function of LZM has always been considered bactericidal,47 even though previous work has shown that it may play a part in the modulation of monocyte-lymphocyte interactions8 and depression of neutrophil chemotaxis.'
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Background -Interstitial lung diseases are characterised by the recruitment of mononuclear cells to disease sites where maturation occurs and activation products, including lysozyme (LZM), are released. Analysis of in vitro cell culture supernatants for activation products masks the functional heterogeneity of cell populations. It is therefore necessary to examine the secretion of activation products by single cells to assess whether the activation ofnewly recruited mononuclear phagocytes at the sites of disease in the lung is uniform and controlled by the local microenvironment. Methods -The reverse haemolytic plaque assay was used to evaluate, at a single cell level, the ability ofbronchoalveolar lavage (BAL) fluid from seven patients with sarcoidosis to activate Ficoll-Hypaque-separated peripheral blood mononuclear cells by comparison with BAL fluid from six normal volunteers and nine patients with systemic sclerosis. Monolayers of peripheral blood mononuclear cells and sheep red blood cells were cultured either alone or in the presence of 20% (vlv) BAL fluid with a polyclonal anti-LZM antibody. LZM/anti-LZM complexes bound to red blood cells surrounding the secreting cells were disclosed following complement lysis of red blood cells and quantification of plaque dimensions using microscopy and image analysis. Results -Bronchoalveolar lavage fluid from all the patients with sarcoidosis increased LZM secretion by peripheral blood mononuclear cells compared with unstimulated mononuclear cells. By contrast, BAL fluid from the other individuals had no effect on LZM secretion.
Conclusions -Single cells activated by BAL fluid can be evaluated by the reverse haemolytic plaque assay. BAL fluid from patients with sarcoidosis, but not from patients with systemic sclerosis or normal individuals, contains components capable of activating mononuclear phagocytes to secrete lysozyme. (Thorax 1994; 49:1146 -1151 Sarcoidosis is characterised by the accumulation at disease sites ofmononuclear cells resulting in the formation of epithelioid cell granulomas."2 Circulating monocytes which are attracted to disease sites are subjected to the influence of local proinflammatory signals resulting in phenotypic and functional changes as they undergo maturation and activation.3 One of the activation products of stimulated mononuclear phagocytes is lysozyme (LZM),4 and measurements of LZM concentration have been used as an index of active disease.56 The primary function of LZM has always been considered bactericidal,47 even though previous work has shown that it may play a part in the modulation of monocyte-lymphocyte interactions8 and depression of neutrophil chemotaxis.'
If monocytes attracted to disease sites in sarcoidosis are stimulated to produce increased amounts of LZM, we hypothesised that factors within the local microenvironment are responsible for this change in function. To test the hypothesis we have used a method of identifying secretory products at the single cell level using the reverse haemolytic plaque assay to examine the effects of bronchoalveolar lavage (BAL) fluid on LZM secretion. The ability of the reverse haemolytic plaque assay to visualise cytokine products by single cells allows the modulation in function of cells to be assessed in the absence of cell-cell interaction and minimises paracrine effects ofproinflammatory mediators from other cells in culture, thus enabling the direct effect of added BAL fluid on cell activation to be analysed. We therefore examined BAL fluid from patients with sarcoidosis, patients with systemic sclerosis, and normal individuals and compared the capacity of each to activate "naive" monocytes to synthesise and secrete LZM.
Methods

PATIENTS
Three groups were studied: (1) patients with sarcoidosis (n=7; M:F 4:3; age 30-2 (1-6) years), (2) patients with fibrosing alveolitis associated with systemic sclerosis (n=9; M:F 4:5; age (1-7) years), and (3) normal volunteers (n=6; M:F 3:3; age 26-3 (046) years). Of the patient groups, two patients with sarcoidosis were current smokers and three with systemic sclerosis were receiving treatment (prednisolone were removed by rinsing each chamber with complete media leaving a confluent monolayer of erythrocytes and peripheral blood mononuclear cells on the poly-L-lysine-coated surface. The chambers were then filled with complete media containing 1/50 dilution of rabbit anti-human LZM (Dakopattis Ltd, High Wycombe, UK) from which sodium azide had been previously removed using an Amicon Concentrator'7 (Amicon Ltd, Gloucestershire, UK), and 20% ((v/v):final dilution in culture chamber) of either normal saline (control) or BAL fluid from patients with sarcoidosis, systemic sclerosis, and normal subjects (the optimum concentration of BAL fluid determined by preliminary experiments). The chambers were incubated for three hours at 37°C in 5% CO2 and then washed with complete media and filled with complete media containing 1/30 dilution of guinea pig complement (Gibco, Uxbridge, UK). After 25 minutes incubation at 37°C in 5% C02, during which period plaques of haemolysis were formed around the LZM-secreting cells, the chambers were washed with complete media without BSA and either fixed with 4% glutaraldehyde in phosphate buffer (pH 7 4) and stored at 4°C under Tris-buffered saline (TBS) prior to estimation of plaque dimensions, or infused with 0 5% (v/v) Trypan Blue solution and incubated for five minutes at 37°C to test the viability of peripheral blood mononuclear cells. Cell viability was always >95% at the end ofthree hours incubation in the reverse haemolytic plaque assay.
The specificity of plaque formation for LZM secretion was confirmed since no haemolytic plaques were observed when (a) mononuclear cells were omitted from the assay; (b) when the anti-LZM antibody was omitted and replaced with 1:50 normal rabbit serum; (c) when complement was omitted; (d) when uncoated erythrocytes were used; (e) when the antibody was preabsorbed at 4°C overnight with >3 ig/ml human LZM (Calbiochem, Nottingham, UK).
To minimise the day to day variations that exist during culturing of the peripheral blood mononuclear cells in the reverse haemolytic plaque assay, even though culturing conditions were stringently observed, each assay contained at least one sample of BAL fluid from each study group examined and a control in which the volume of BAL fluid was substituted with normal saline.
IMMUNOSTAINING OF MONOCYTES
At the end of the assay the plaque-forming cells were identified as monocytes by immunolabelling with KP1 mouse monoclonal antibody (gift from Dr DY Mason, Oxford, UK) which recognises proteins of 110, 70, and 40 kDa expressed in the lysosomal fraction of mononuclear phagocytes.18 Visualisation of positively staining cells was achieved using the alkaline phosphatase/anti-alkaline phosphatase (APAAP) immunocytochemical method'9 employing a 1/50 dilution of rabbit anti-mouse IgG, 1/50 dilution of APAAP complex, alkaline phosphatase substrate, and fast red with haematoxylin counterstaining. After colour development the chambers were dried, the coverslip removed, and a new coverslip mounted. To determine whether the leakag factors due to increased vascular p or the volume of lavage return cot for the observed between-group diff assayed BAL fluid for albumin, a known to be synthesised within the parenchyma, and measured the pe instilled fluid which was returned pared these data between grot albumin concentrations (duplicat ments) were not different between (table) . Similarly, the range of flt were comparable (data not shown) Mean (SE) and range of lysozyme and albumin levels in the bronchoalveol fluid from patients with sarcoidosis, systemic sclerosis and normal subjects Group Lysozyme (pg/mi) Albumin (mg/ml, In systemic sclerosis, a condition in which mononuclear phagocytes also traffic to disease sites and also release potent mediators -including tumour necrosis factor alpha and interleukin-83233 -which can modulate the disease process, other control mechanisms are likely to be involved in stimulating monocytes to produce a quite distinct repertoire of mediators which are, therefore, disease dependent.
The reverse haemolytic plaque assay has a number of advantages over traditional culture methods. Firstly, although the assay cannot completely abrogate paracrine effects, the small volume of the incubation chamber makes these much less likely, particularly as cells isolated from other cells were chosen for measurement. Secondly, visualisation of products of single cells provides the added advantage of combining this with immunocytochemical staining using specific monoclonal antibodies which will allows changes in surface phenotype to be related to plaque formation (that is, function) and this is the subject of further studies. Thirdly, our preliminary studies using pure LZM have confirmed that the assay is specific for LZM secretion. This method therefore allows a much more complete dissection of individual cell functions to be undertaken.
In conclusion, we have shown that epithelial lining fluid obtained from patients with sarcoidosis can modulate the function of peripheral blood mononuclear cells which implies that newly arriving monocytes at disease sites receive specific stimulatory signals which define their functional role within the disease process. Furthermore, we have shown that there is heterogeneity within the monocyte population in terms of amount of LZM produced per cell, and that the stimulatory activity is found only in lavage fluid obtained from patients with sarcoidosis. The reverse haemolytic plaque assay will allow the further exploration of subpopulations of mononuclear phagocytes to be undertaken with particular regard to their secretory repertoire, and this may provide greater insights into the regulation of mononuclear phagocyte function in the lung at disease sites.
